Quantum Cyber N.V. current report, Q4 FY2021

Business Context and Reporting Period

This Form 6-K filing covers the month of November 2021 for Mainz Biomed N.V. (Note: The request metadata references "Quantum Cyber N.V.", but the filing text explicitly identifies the registrant as Mainz Biomed N.V.). The report details a corporate conversion from a private limited liability company to a Dutch public company with limited liability (naamloze vennootschap) and the completion of an initial public offering (IPO).

Key Financial Metrics

The filing does not provide historical revenue, profit, cash flow, or margin data. The primary financial event reported is the capital raise from the public offering:

  • Gross Proceeds: Approximately $11.5 million (2,300,000 shares sold at $5.00 per share).
  • Net Proceeds: Approximately $10,358,750 after deducting underwriting discounts, commissions, and offering expenses.
  • Underwriting Fees: 7% cash fee plus 0.75% non-accountable expense allowance.
  • Warrants Issued: 161,000 Representative's Warrants exercisable at $5.50 per share.

Material Changes

The following material changes occurred during the reporting period:

  • Corporate Structure: Converted to a Dutch public company (naamloze vennootschap) on November 9, 2021.
  • Board Composition: Dr. Moritz Eidens, Alberto Libanori, Nicole Holden, and Hans Hekland joined the Board of Directors. Marco Messina resigned as a director.
  • Public Listing: Ordinary shares began trading on the Nasdaq Capital Market under the symbol "VMAR" on November 5, 2021.
  • Capitalization: Issued 2,300,000 ordinary shares, including 300,000 shares from the full exercise of the over-allotment option.

Outlook, Risks, and Contingencies

Lock-Up Agreements: The company, its directors, executive officers, and pre-offering shareholders are subject to a 180-day lock-up period prohibiting the sale or transfer of securities without underwriter consent.

Management Commentary: The filing confirms that the articles of association were amended to reflect the public company status and that the Registration Statement on Form F-1 accurately summarized these terms.

Risks: The filing notes that representations and warranties in the Underwriting Agreement were made solely for the benefit of the contracting parties and may be subject to limitations.

Investor Verification Checklist

  • Verify the ticker symbol "VMAR" on the Nasdaq Capital Market.
  • Confirm the net proceeds of approximately $10.36 million received from the offering.
  • Review the amended articles of association following the Deed of Conversion.
  • Monitor the 180-day lock-up expiration date for potential share sales by insiders.
  • Check the exercise terms of the 161,000 warrants issued to the underwriter.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.